LEADER 02042nam  2200469   450 
001 9910706553103321
005 20180705162203.0
035   $a(CKB)5470000002456916
035   $a(OCoLC)1013542208
035   $a(EXLCZ)995470000002456916
100   $a20171130d2017      ua             0
101 0 $aeng
135   $aurbn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aExamining the impact of voluntary restricted distribution systems in the pharmaceutical supply chain $ehearing before the Subcommittee on Healthcare, Benefits, and Administrative Rules of the Committee on Oversight and Government Reform, House of Representatives, One Hundred Fifteenth Congress, first session, March 22, 2017
210  1$aWashington :$cU.S. Government Publishing Office,$d2017.
215   $a1 online resource (iii, 54 pages)
300   $a"Serial no. 115-33."
300   $aPaper version available for sale by the Superintendent of Documents, U.S. Government Publishing Office.
320   $aIncludes bibliographical references.
517   $aExamining the impact of voluntary restricted distribution systems in the pharmaceutical supply chain 
606   $aPharmaceutical industry$xCorrupt practices$zUnited States
606   $aPharmaceutical policy$zUnited States
606   $aGeneric drugs$xDevelopment$zUnited States
606   $aPrescription pricing$zUnited States
606   $aCompetition$zUnited States
606   $aConsumer protection$zUnited States
608   $aLegislative hearings.$2lcgft
615  0$aPharmaceutical industry$xCorrupt practices
615  0$aPharmaceutical policy
615  0$aGeneric drugs$xDevelopment
615  0$aPrescription pricing
615  0$aCompetition
615  0$aConsumer protection
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910706553103321
996   $aExamining the impact of voluntary restricted distribution systems in the pharmaceutical supply chain$93533448
997   $aUNINA